CCR9 and inflammatory bowel disease: Interestingly, also in human clinical trials, using a ccr9 antagonist to reduce ccr9 gene expression has been modelled as an effective treatment in preventing inflammatory bowel disease, a chronic inflammation of the gastrointestinal tract that causes long-term tissue damages and often irreversible impairment of the structure and functions [57].